ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average - Should You Sell?

Key Points

• ImmuCell Corporation (NASDAQ: ICCC) shares have surpassed their 200-day moving average, trading at $6.25, with a high of $6.70 during recent trading sessions.
• The biotechnology company reported a net revenue of $6.45 million for the last quarter, with earnings per share of $0.06 and a return on equity of 6.25%.
• Institutional investors own 13.47% of ImmuCell's stock, with notable recent purchases by firms such as Citadel Advisors and Northern Trust Corp.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.98 and traded as high as $6.70. ImmuCell shares last traded at $6.25, with a volume of 106,213 shares changing hands.

ImmuCell Stock Performance

The company has a 50 day moving average price of $6.24 and a 200-day moving average price of $5.98. The company has a current ratio of 3.85, a quick ratio of 1.99 and a debt-to-equity ratio of 0.28. The company has a market cap of $56.56 million, a P/E ratio of 32.90 and a beta of 0.29.

ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The company had revenue of $6.45 million for the quarter.

Institutional Investors Weigh In On ImmuCell

Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of ImmuCell during the 4th quarter valued at $149,000. Northern Trust Corp boosted its holdings in shares of ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after acquiring an additional 2,907 shares in the last quarter. Institutional investors and hedge funds own 13.47% of the company's stock.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.